1. Articles from Atox Bio

    1-1 of 1
    1. Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of

      "We appreciate and continue to benefit from BARDA's ongoing support in the development of Reltecimod as a novel, host-based, immunomodulatory therapy to treat severe infections," said Dan Teleman, Chief Executive Officer of Atox Bio. "We have a very collaborative partnership with BARDA and look forward to continuing to work together." Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor to modulate the host's immune response to severe infections. By limiting, but not inhibiting, the body's acute inflammatory response, Reltecimod helps control the cytokine storm that could quickly lead to morbidity and mortality ...

      Read Full Article
      Mentions: Yissum
    1-1 of 1
  1. Categories

    1. News:

      News, Placeholder
  2. Topics in the News

    1. (1 articles) Yissum
  3. Popular Articles

  4. Picture Gallery

    Atox Bio Awarded Next Milestone-based Option by BARDA to Support Continued Development of Parshat Pinhas: Zelophehad only h... Penn Dental Renews Exchange with Hebrew University-Hadassah School of Dental Medicine - Penn Dental Medicine Neanderthal Settlement Where Our Prehistoric Relatives Lived for 10,000 Years Discovered in Israel Forget sperm and eggs, researchers have created embryo stem cells from skin cells Commentary: A Huge Leap for Microscopic Health Treatments Hebrew University hosts cannabis conference to forge way forward Israel and Finland launch digital health collaboration | ISRAEL21c Best boutique hotels in Israel for 2019 Spring Newsletter 2019: Growing Possibilities, Broadening Our Reach Scientists get sly, use deception to fight cancer - EurekAlert Israelis Design Tiny Toys For Kinder Eggs In Hebrew University Course